Blood tests could reveal inflammation in methamphetamine users
NCT ID NCT07450027
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measures two blood proteins, LRFN5 and OLFM4, in people with methamphetamine use disorder, those with methamphetamine-induced psychosis, and healthy volunteers. Researchers want to see if these markers are linked to inflammation and symptom severity. The study involves 120 participants and does not test any treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help identify blood markers that indicate inflammation or severity of symptoms in methamphetamine-related disorders.
What could go wrong
This is an early observational study, not a treatment trial. It may not find clear links between the markers and the conditions, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METHAMPHETAMINE USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Elazığ Mental Health and Diseases Hospital
RECRUITINGElâzığ, Elâzığ, 23200, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••